Item 1. Financial Statements
SPHERIX INCORPORATED AND SUBSIDIARIES
Condensed Consolidated Balance Sheets
($ in thousands except per share amounts)
|
|
June 30
|
|
|
December 31
|
|
|
|
2016
|
|
|
2015
|
|
|
|
(Unaudited)
|
|
|
|
|
ASSETS
|
|
|
|
|
|
|
|
|
Current assets
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
392
|
|
|
$
|
142
|
|
Marketable securities
|
|
|
5,671
|
|
|
|
3,392
|
|
Prepaid expenses and other assets
|
|
|
99
|
|
|
|
330
|
|
Total current assets
|
|
|
6,162
|
|
|
|
3,864
|
|
|
|
|
|
|
|
|
|
|
Property and equipment, net
|
|
|
7
|
|
|
|
5
|
|
Patent portfolios and patent rights, net
|
|
|
8,737
|
|
|
|
9,799
|
|
Deposit
|
|
|
26
|
|
|
|
26
|
|
Total assets
|
|
$
|
14,932
|
|
|
$
|
13,694
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS' EQUITY
|
|
|
|
|
|
|
|
|
Current liabilities
|
|
|
|
|
|
|
|
|
Accounts payable and accrued expenses
|
|
$
|
260
|
|
|
$
|
384
|
|
Accrued salaries and benefits
|
|
|
74
|
|
|
|
645
|
|
Warrant liabilities
|
|
|
1,928
|
|
|
|
2,959
|
|
Short-term deferred revenue
|
|
|
1,246
|
|
|
|
290
|
|
Short-term lease liabilities
|
|
|
179
|
|
|
|
178
|
|
Total current liabilities
|
|
|
3,687
|
|
|
|
4,456
|
|
|
|
|
|
|
|
|
|
|
Long-term deferred revenue
|
|
|
3,843
|
|
|
|
259
|
|
Long-term lease liabilities
|
|
|
138
|
|
|
|
229
|
|
Total liabilities
|
|
|
7,668
|
|
|
|
4,944
|
|
|
|
|
|
|
|
|
|
|
Series I redeemable convertible preferred stock, $0.0001 par value; no shares issued and outstanding at June 30, 2016 and December 31, 2015; liquidation preference of $167 per share
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
Commitments and contingencies
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders' equity
|
|
|
|
|
|
|
|
|
Preferred Stock, $0.0001 par value, 50,000,000 shares authorized;
|
|
|
|
|
|
|
|
|
Series A: no shares issued and outstanding at June 30, 2016 and December 31, 2015; liquidation preference $0.0001 per share
|
|
|
|
|
|
|
|
|
Convertible preferred stock
|
|
|
-
|
|
|
|
-
|
|
Series C: no shares issued and outstanding at June 30, 2016 and December 31, 2015; liquidation preference $0.0001 per share
|
|
|
-
|
|
|
|
-
|
|
Series D: 4,725 shares issued and outstanding at June 30, 2016 and December 31, 2015; liquidation value of $0.0001 per share
|
|
|
-
|
|
|
|
-
|
|
Series D-1: 834 shares issued and outstanding at June 30, 2016 and December 31, 2015; liquidation value of $0.0001 per share
|
|
|
-
|
|
|
|
-
|
|
Series F-1: no shares issued and outstanding at June 30, 2016 and December 31, 2015; liquidation preference $0.0001 per share
|
|
|
-
|
|
|
|
-
|
|
Series H: no shares and 381,967 shares issued and outstanding at June 30, 2016 and December 31, 2015, respectively; liquidation preference $83.50 per share
|
|
|
-
|
|
|
|
-
|
|
Series J: no shares issued and outstanding at June 30, 2016 and December 31, 2015; liquidation preference $0.0001 per share
|
|
|
-
|
|
|
|
-
|
|
Series K: no shares and 1,240 shares issued and outstanding at June 30, 2016 and December 31, 2015, respectively; liquidation preference $1,000 per share
|
|
|
-
|
|
|
|
-
|
|
Common stock, $0.0001 par value, 100,000,000 shares authorized; 3,228,612 and 2,539,859 shares issued at June 30, 2016 and December 31, 2015, respectively; 3,228,600 and 2,539,847 shares outstanding at June 30, 2016 and December 31, 2015, respectively
|
|
|
-
|
|
|
|
-
|
|
Additional paid-in-capital
|
|
|
144,928
|
|
|
|
144,287
|
|
Treasury stock, at cost, 12 shares at June 30, 2016 and December 31, 2015
|
|
|
(264
|
)
|
|
|
(264
|
)
|
Accumulated deficit
|
|
|
(137,400
|
)
|
|
|
(135,273
|
)
|
Total stockholders' equity
|
|
|
7,264
|
|
|
|
8,750
|
|
Total liabilities and stockholders' equity
|
|
$
|
14,932
|
|
|
$
|
13,694
|
|
See accompanying notes to condensed consolidated
financial statements
SPHERIX INCORPORATED AND SUBSIDIARIES
Condensed Consolidated Statements of
Operations
($ in thousands except per share amounts)
(Unaudited)
|
|
Three Months Ended June 30,
|
|
|
Six Months Ended June 30,
|
|
|
|
2016
|
|
|
2015
|
|
|
2016
|
|
|
2015
|
|
Revenues
|
|
$
|
177
|
|
|
$
|
-
|
|
|
$
|
249
|
|
|
$
|
2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating costs and expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization of patent portfolio
|
|
|
531
|
|
|
|
2,450
|
|
|
|
1,062
|
|
|
|
4,872
|
|
Compensation and related expenses (including stock-based compensation)
|
|
|
361
|
|
|
|
(54
|
)
|
|
|
673
|
|
|
|
665
|
|
Professional fees
|
|
|
824
|
|
|
|
551
|
|
|
|
1,529
|
|
|
|
1,280
|
|
Impairment of goodwill and intangible assets
|
|
|
-
|
|
|
|
37,212
|
|
|
|
-
|
|
|
|
37,212
|
|
Rent
|
|
|
23
|
|
|
|
22
|
|
|
|
45
|
|
|
|
44
|
|
Other selling, general and administrative
|
|
|
60
|
|
|
|
122
|
|
|
|
123
|
|
|
|
348
|
|
Total operating expenses
|
|
|
1,799
|
|
|
|
40,303
|
|
|
|
3,432
|
|
|
|
44,421
|
|
Loss from operations
|
|
|
(1,622
|
)
|
|
|
(40,303
|
)
|
|
|
(3,183
|
)
|
|
|
(44,419
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other (expenses) income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income (expenses), net
|
|
|
55
|
|
|
|
(5
|
)
|
|
|
25
|
|
|
|
25
|
|
Change in fair value of warrant liabilities
|
|
|
(511
|
)
|
|
|
-
|
|
|
$
|
1,031
|
|
|
|
-
|
|
Total other (expenses) income
|
|
|
(456
|
)
|
|
|
(5
|
)
|
|
|
1,056
|
|
|
|
25
|
|
Net loss
|
|
$
|
(2,078
|
)
|
|
$
|
(40,308
|
)
|
|
$
|
(2,127
|
)
|
|
$
|
(44,394
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Deemed capital contribution on extinguishment of preferred stock
|
|
|
31,480
|
|
|
|
-
|
|
|
|
31,480
|
|
|
|
-
|
|
Net income (loss) attributable to common stockholders
|
|
$
|
29,402
|
|
|
$
|
(40,308
|
)
|
|
$
|
29,353
|
|
|
$
|
(44,394
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) per share attributable to common stockholders, basic and diluted
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
$
|
9.61
|
|
|
$
|
(26.76
|
)
|
|
$
|
10.18
|
|
|
$
|
(29.48
|
)
|
Diluted
|
|
$
|
9.21
|
|
|
$
|
(26.76
|
)
|
|
$
|
9.32
|
|
|
$
|
(29.48
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average number of common shares outstanding,
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
|
3,060,455
|
|
|
|
1,506,221
|
|
|
|
2,883,160
|
|
|
|
1,506,055
|
|
Diluted
|
|
|
3,193,227
|
|
|
|
1,506,221
|
|
|
|
3,147,021
|
|
|
|
1,506,055
|
|
See accompanying notes to condensed consolidated
financial statements
SPHERIX INCORPORATED AND SUBSIDIARIES
Condensed Consolidated Statements of
Cash Flows
($ in thousands)
(Unaudited)
|
|
Six Months Ended June 30,
|
|
|
|
2016
|
|
|
2015
|
|
Cash flows from operating activities
|
|
|
|
|
|
|
|
|
Net loss
|
|
$
|
(2,127
|
)
|
|
$
|
(44,394
|
)
|
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
|
|
|
|
|
|
|
|
|
Amortization of patent portfolio
|
|
|
1,062
|
|
|
|
4,872
|
|
Change in fair value of warrant liabilities
|
|
|
(1,031
|
)
|
|
|
-
|
|
Stock-based compensation
|
|
|
299
|
|
|
|
134
|
|
Depreciation expenses
|
|
|
1
|
|
|
|
1
|
|
Realized loss on marketable securities
|
|
|
57
|
|
|
|
61
|
|
Unrealized gain on marketable securities
|
|
|
(29
|
)
|
|
|
(45
|
)
|
Impairment of goodwill and intangible assets
|
|
|
-
|
|
|
|
37,212
|
|
Changes in assets and liabilities:
|
|
|
|
|
|
|
|
|
Prepaid expenses and other assets
|
|
|
231
|
|
|
|
34
|
|
Accounts payable and accrued expenses
|
|
|
(124
|
)
|
|
|
(217
|
)
|
Accrued salaries and benefits
|
|
|
(571
|
)
|
|
|
(64
|
)
|
Deferred revenue
|
|
|
4,126
|
|
|
|
-
|
|
Accrued lease liabilities
|
|
|
(90
|
)
|
|
|
(86
|
)
|
Net cash provided by (used in) operating activities
|
|
|
1,804
|
|
|
|
(2,492
|
)
|
|
|
|
|
|
|
|
|
|
Cash flows from investing activities
|
|
|
|
|
|
|
|
|
Purchase of marketable securities
|
|
|
(10,193
|
)
|
|
|
(3,774
|
)
|
Purchase of property and equipment
|
|
|
(3
|
)
|
|
|
-
|
|
Sale of marketable securities
|
|
|
7,886
|
|
|
|
6,483
|
|
Net cash (used in) provided by investing activities
|
|
|
(2,310
|
)
|
|
|
2,709
|
|
|
|
|
|
|
|
|
|
|
Cash flows from financing activities
|
|
|
|
|
|
|
|
|
Cash paid for cancellation of common stocks
|
|
|
(4
|
)
|
|
|
-
|
|
Proceeds from exercise of warrants
|
|
|
760
|
|
|
|
-
|
|
Redemption of Series I redeemable convertible preferred stock
|
|
|
-
|
|
|
|
(935
|
)
|
Net cash provided by (used in) financing activities
|
|
|
756
|
|
|
|
(935
|
)
|
|
|
|
|
|
|
|
|
|
Net increase (decrease) in cash and cash equivalents
|
|
|
250
|
|
|
|
(718
|
)
|
Cash and cash equivalents, beginning of period
|
|
|
142
|
|
|
|
805
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents, end of period
|
|
$
|
392
|
|
|
$
|
87
|
|
|
|
|
|
|
|
|
|
|
Cash paid for interest and taxes
|
|
$
|
-
|
|
|
$
|
-
|
|
|
|
|
|
|
|
|
|
|
Non-cash investing and financing activities
|
|
|
|
|
|
|
|
|
Extinguishment of Series H Convertible Preferred Stock in connection with license agreement
|
|
$
|
31,480
|
|
|
$
|
-
|
|
Recognition of deferred revenue in connection with license agreement
|
|
$
|
414
|
|
|
$
|
-
|
|
See accompanying notes to condensed consolidated
financial statements
Note 1. Organization and Description of Business
|
Organization and Description of Business
Spherix Incorporated (the “Company”)
is an intellectual property company incorporated in the State of Delaware that owns patented and unpatented intellectual property.
The Company was formed in 1967 as a scientific research company and for much of its history pursued drug development including
through Phase III clinical studies which were discontinued. Through the Company’s acquisition of patents and patent applications
developed by Nortel Networks Corporation from Rockstar Consortium US, LP (“Rockstar”) and Harris Corporation from North
South Holdings Inc. (“North South”) in 2013, the Company has expanded its activities and is a significant owner of
intellectual property assets.
The Company is a patent commercialization
company focused on generating revenues from the monetization of intellectual property, or IP. Such monetization includes,
but is not limited to, acquiring IP from patent holders in order to maximize the value of the patent holdings by conducting and
managing a licensing campaign, or through the settlement and litigation of patents. We intend to generate revenues and related
cash flows from the granting of intellectual property rights for the use of patented technologies that we own, or that we manage
for others. To date, we have generated minimal revenues and no assurance can be provided that our business model will be successful.
We continually work to enhance our portfolio
of intellectual property through acquisition and strategic partnerships. Our mission is to partner with inventors, or other entities,
who own undervalued intellectual property. We then work with the inventors or other entities to commercialize the IP.
In March 2016, the Company entered into an agreement (which was subsequently amended in April and
May 2016) with Equitable IP Corporation (“Equitable”) to facilitate the monetization of its patents
(the “Monetization Agreement”). Pursuant to the Monetization Agreement, the Company will work together with
Equitable to further develop and revise its ongoing litigation plan. See Note 4 for additional details surrounding the
Monetization Agreement.
Reverse Stock Split and Amendment to
Certificate of Incorporation
The Company’s common stock is listed
on the NASDAQ Capital Market under the symbol “SPEX.” One of the requirements for continued listing on the NASDAQ Capital
Market is maintenance of a minimum closing bid price of $1.00 per share. On March 24, 2015, the Company received a letter (the
“Notice”) from the Listing Qualifications Staff of The NASDAQ Stock Market LLC (“NASDAQ”) notifying the
Company that, based upon the closing bid price of the Company’s common stock, $0.0001 par value per share (the “Common
Stock”) for the 30 consecutive business days preceding receipt of such letter, the Common Stock had no longer met the requirement
to maintain a minimum closing bid price of $1.00 per share, as set forth in NASDAQ Listing Rule 5550(a)(2).
In accordance with NASDAQ’s Listing
Rule 5810(c)(3)(A), the Company initially had a period of 180 calendar days, or until September 21, 2015, to regain compliance
with the Rule. After determining that it would not be in compliance with the Rule by September 21, 2015, the Company notified NASDAQ
and applied for an extension of the cure period, as permitted under the original notification. In accordance with NASDAQ Listing
Rule 5810(c)(3)(A), NASDAQ granted a second grace period of 180 calendar days, or until March 21, 2016, to regain compliance with
the minimum closing bid price requirement for continued listing.
On February 26, 2016, the Company’s
stockholders approved an amendment to the Company’s certificate of incorporation and authorized the Company’s Board
of Directors to effect a reverse stock split of Common Stock at a ratio in the range of 1-for-12 to 1-for-24. The Company implemented
this reverse stock split on March 4, 2016 with a ratio of 1-for-19 (the “Reverse Stock Split”). No fractional shares
were issued in connection with the Reverse Stock Split. Stockholders who otherwise would have been entitled to receive a fractional
share in connection with the Reverse Stock Split received a cash payment in lieu thereof. The par value and other terms of the
common stock were not affected by the Reverse Stock Split. In addition, the amendment to the Company’s certificate of incorporation
that effected the Reverse Stock Split also simultaneously reduced the number of authorized shares of Common Stock from 200,000,000
to 100,000,000.
The Company’s Common Stock began
trading at its post-Reverse Stock Split price at the beginning of trading on March 4, 2016.
On March 18, 2016, the Company received
a letter from NASDAQ indicating that it had regained compliance with the minimum bid price requirement under NASDAQ Listing Rule
5550(a)(2) for continued listing on The NASDAQ Capital Market. The Company’s common stock continues to be listed on the NASDAQ
Capital Market.
Immediately following the Reverse Stock
Split, the number of outstanding shares of Common Stock were reduced from 48,259,430 shares to 2,539,847. All per share amounts
and outstanding shares of Common Stock including stock options, restricted stock and warrants, have been retroactively adjusted
in these condensed consolidated financial statements for all periods presented to reflect the 1-for-19 Reverse Stock Split. Further,
exercise prices of stock options and warrants have been retroactively adjusted in these condensed consolidated financial statements
for all periods presented to reflect the 1-for-19 Reverse Stock Split. Numbers of shares of the Company’s preferred stock
were not affected by the Reverse Stock Split; however, the conversion ratios have been adjusted to reflect the Reverse Stock Split.
Note 2. Liquidity and Financial Condition
The Company continues to incur ongoing
administrative and other expenses, including public company expenses, in excess of corresponding (non-financing related) revenue.
While the Company continues to implement its business strategy, it intends to finance its activities through:
|
·
|
managing current cash and cash equivalents on hand from the Company’s past equity offerings,
|
|
·
|
seeking additional funds raised through the sale of additional securities in the future,
|
|
·
|
seeking additional liquidity through credit facilities or other debt arrangements, and
|
|
·
|
increasing revenue from its patent portfolios, license fees and new business ventures.
|
As a result of the Company’s recurring
operating losses and net operating cash flow deficits, there is substantial doubt about the Company’s ability to continue
as a going concern. The condensed consolidated financial statements have been prepared assuming the Company will continue
as a going concern and do not include any adjustments to reflect the possible future effects on the recoverability and classification
of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty.
The Company’s ultimate success is
dependent on its ability to obtain additional financing and generate sufficient cash flow to meet its obligations on a timely basis. The
Company’s business will require significant amounts of capital to sustain operations and make the investments it needs to
execute its longer term business plan. The Company’s working capital amounted to approximately $2.5 million at
June 30, 2016, and net loss amounted to approximately $2.1 million and $2.1 million for the three and six months ended June 30,
2016, respectively. The Company had an approximately $137.4 million of accumulated deficit as of June 30, 2016. The
Company’s existing liquidity is not sufficient to fund its operations, anticipated capital expenditures, working capital
and other financing requirements for the foreseeable future. Absent generation of sufficient revenue from the execution
of the Company’s business plan, the Company will need to obtain additional debt or equity financing, especially if the Company
experiences downturns in its business that are more severe or longer than anticipated, or if the Company experiences significant
increases in expense levels resulting from being a publicly-traded company or operations. If the Company attempts to
obtain additional debt or equity financing, the Company cannot assume that such financing will be available to the Company on favorable
terms, or at all.
Disputes regarding the assertion of patents
and other intellectual property rights are highly complex and technical. The Company may be forced to litigate against others to
enforce or defend its intellectual property rights or to determine the validity and scope of other parties’ proprietary rights.
The defendants or other third parties involved in the lawsuits in which the Company is involved may allege defenses and/or file
counterclaims or initiate inter parties reviews in an effort to avoid or limit liability and damages for patent infringement or
cause the Company to incur additional costs as a strategy. If such efforts are successful, they may have an impact on
the value of the patents and preclude the Company from deriving revenue from the patents. The patents could be declared invalid
by a court or the United States Patent and Trademark Office, in whole or in part, or the costs of the Company can increase. Recent
rulings also create an increased risk that if the Company is unsuccessful in litigation it could be responsible to pay the attorneys’
fees and other costs of defendants by lowering the standard for legal fee shifting sought by defendants in patent cases.
As a result, a negative outcome of any
such litigation, or one or more claims contained within any such litigation, could materially and adversely impact the Company’s
business. Additionally, the Company anticipates that legal fees which are not included in contingency fee arrangements, experts
and other expenses will be material and could have an adverse effect on its financial condition and results of operations if its
efforts to monetize its patents are unsuccessful.
In addition, the costs of enforcing the
Company’s patent rights may exceed its recoveries from such enforcement activities. Accordingly, in order for
the Company to generate a profit from its patent enforcement and monetization activities, the revenues from such enforcement and
monetization activities must be high enough to offset both the cash outlays and the contingent fees payable from such revenues,
including any profit sharing arrangements with inventors or prior owners of the patents. The Company’s failure to monetize
its patent assets or the occurrence of unforeseen circumstances that could have a negative impact on the Company’s liquidity
could significantly harm its business.
Note 3. Summary of Significant Accounting Policies
Significant Accounting Policies
There have been no material changes in
the Company’s significant accounting policies other than described below to those previously disclosed in the 2015 Annual
Report on Form 10-K filed with the U.S. Securities and Exchange Commission on March 29, 2016.
Basis of Presentation and Principles
of Consolidation
The accompanying condensed consolidated
financial statements of the Company are unaudited and do not include all of the information and disclosures generally required
for annual financial statements. In the opinion of management, the statements contain all material adjustments (consisting of normal
recurring accruals) necessary to present fairly the Company’s condensed consolidated financial position as of June 30, 2016,
and the condensed consolidated results of its operations for the three and six months ended June 30, 2016 and 2015, and the condensed
consolidated results of its cash flows for the six months ended June 30, 2016 and 2015. This report should be read in conjunction
with the Company’s 2015 Annual Report on Form 10-K, which does contain the complete information and disclosure for the year
ended December 31, 2015.
The accompanying condensed consolidated
financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany balances
and transactions have been eliminated in consolidation.
Use of Estimates
The accompanying condensed consolidated
financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America
(“US GAAP”). This requires management to make estimates and assumptions that affect certain reported amounts of assets
and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, and the reported
amounts of revenue and expenses during the period. The Company’s significant estimates and assumptions include the recoverability
and useful lives of long-lived assets, stock-based compensation, the valuation of derivative liabilities, and the valuation allowance
related to the Company’s deferred tax assets. Certain of the Company’s estimates, including the carrying amount of
the intangible assets, could be affected by external conditions, including those unique to the Company and general economic conditions.
It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual
results to differ from those estimates and assumptions.
Reclassification
Certain reclassifications have been made
to prior year amounts to conform to the current year presentation on the condensed consolidated statements of cash flows.
Marketable Securities
Marketable securities are classified as
trading and are carried at fair value. The Company’s marketable securities consist of corporate bonds as of June 30, 2016,
and consisted of highly liquid mutual funds and exchange-traded & closed-end funds during 2015.
During the three months ended June 30,
2016 and 2015, the Company incurred realized gains of approximately $10,000 and realized losses $8,000, respectively, and unrealized
gains of approximately $17,000 and loss of $12,000, respectively, on its investments in marketable securities, which
are included in other income, net on the condensed consolidated statements of operations. In addition, during the three
months ended June 30, 2016 and 2015, the Company earned dividend income of approximately $4,000 and $15,000, respectively,
which is included in other income, net on the condensed consolidated statement of operations.
During the six months ended June 30,
2016 and 2015, the Company incurred realized losses of approximately $57,000 and $61,000, respectively, and unrealized gains of
approximately $29,000 and loss of $45,000, respectively, on its investments in marketable securities, which are included
in other income, net on the condensed consolidated statements of operations. In addition, during the six months ended
June 30, 2016 and 2015, the Company earned dividend income of approximately $17,000 and $41,000, respectively, which is included
in other income, net on the condensed consolidated statement of operations. The fair values of marketable
securities held as of June 30, 2016 and December 31, 2015 were approximately $5.7 million and $3.4 million, respectively.
Impairment of Long-lived Assets (Including
Patent Assets)
The Company monitors the carrying value
of long-lived assets for potential impairment and tests the recoverability of such assets whenever events or changes in circumstances
indicate that the carrying amounts may not be recoverable. If a change in circumstance occurs, the Company performs a test of recoverability
by comparing the carrying value of the asset or asset group to its undiscounted expected future cash flows. If cash flows cannot
be separately and independently identified for a single asset, the Company will determine whether impairment has occurred for the
group of assets for which the Company can identify the projected cash flows. If the carrying values are in excess of undiscounted
expected future cash flows, the Company measures any impairment by comparing the fair value of the asset or asset group to its
carrying value. There were no indicators of impairment during the first half of 2016.
Accounting for Warrants
The Company accounts for the issuance of
common stock purchase warrants issued in connection with its previously consummated equity offerings in accordance with the provisions
of ASC 815, Derivatives and Hedging (“ASC 815”). The Company classifies as equity any contracts that (i) require physical
settlement or net-share settlement or (ii) gives the Company a choice of net-cash settlement or settlement in its own shares (physical
settlement or net-share settlement). The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement
(including a requirement to net-cash settle the contract if an event occurs and if that event is outside the control of the Company)
or (ii) gives the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement).
In addition, Under ASC 815, registered common stock warrants that require the issuance of registered shares upon exercise and do
not expressly preclude an implied right to cash settlement are accounted for as derivative liabilities. The Company classifies
these derivative warrant liabilities on the condensed consolidated balance sheet as a current liability.
The Company assessed the classification
of common stock purchase warrants as of the date of each offering and determined that such instruments met the criteria for liability
classification. Accordingly, the Company classified the warrants as a liability at their fair value and adjusts the instruments
to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until the warrants
are exercised or expired, and any change in fair value is recognized as “change in the fair value of warrant liabilities”
in the consolidated statements of operations. The fair value of the warrants has been estimated using a Black-Scholes valuation
model (see Note 5).
Convertible Preferred Stock
The Company has evaluated its convertible
preferred stock and warrants in accordance with the provisions of ASC 815, Derivatives and Hedging, including consideration of
embedded derivatives requiring bifurcation. The issuance of the convertible preferred stock could generate a beneficial conversion
feature (“BCF”), which arises when a debt or equity security is issued with an embedded conversion option that is beneficial
to the investor or in the money at inception because the conversion option has an effective strike price that is less than the
market price of the underlying stock at the commitment date. The Company recognized the BCF by allocating the intrinsic value of
the conversion option, which is the number of shares of common stock available upon conversion multiplied by the difference between
the effective conversion price per share and the fair value of common stock per share on the commitment date, to additional paid-in
capital, resulting in a discount on the convertible preferred stock. As the convertible preferred stock may be converted immediately,
the Company recognized the BCF as a deemed dividend in the condensed consolidated statements of operations.
Net Loss per Share
Basic loss per share is computed by dividing
the net income or loss applicable to common shares by the weighted average number of common shares outstanding during the period.
Diluted earnings per share is computed using the weighted average number of common shares and, if dilutive, potential common shares
outstanding during the period. Potential common shares consist of the incremental common shares issuable upon the exercise of stock
options (using the treasury stock method) and the conversion of the Company’s convertible preferred stock and warrants (using
the if-converted method). Diluted loss per share excludes the shares issuable upon the conversion of preferred stock and the exercise
of stock options and warrants from the calculation of net loss per share if their effect would be anti-dilutive.
The following table summarizes the earnings
(loss) per share calculation (in thousands, except per share amount):
|
|
For the Three Months Ended June 30,
|
|
|
For the Six Months Ended June 30,
|
|
|
|
2016
|
|
|
2015
|
|
|
2016
|
|
|
2015
|
|
Basic earnings per share
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Numerator:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Loss
|
|
$
|
(2,078
|
)
|
|
$
|
(40,308
|
)
|
|
$
|
(2,127
|
)
|
|
$
|
(44,394
|
)
|
Deemed capital contribution on extinguishment of preferred stock
|
|
|
31,480
|
|
|
|
-
|
|
|
|
31,480
|
|
|
|
-
|
|
Net income (loss) available to common stockholders
|
|
$
|
29,402
|
|
|
$
|
(40,308
|
)
|
|
$
|
29,354
|
|
|
$
|
(44,394
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Denominator:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average number of common shares outstanding,
|
|
|
3,060,455
|
|
|
|
1,506,221
|
|
|
|
2,883,160
|
|
|
|
1,506,055
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings per basic share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Loss
|
|
|
(0.68
|
)
|
|
|
(26.76
|
)
|
|
|
(0.74
|
)
|
|
|
(29.48
|
)
|
Deemed capital contribution on extinguishment of preferred stock
|
|
|
10.29
|
|
|
|
-
|
|
|
|
10.92
|
|
|
|
-
|
|
Net income (loss) available to common stockholders
|
|
$
|
9.61
|
|
|
$
|
(26.76
|
)
|
|
$
|
10.18
|
|
|
$
|
(29.48
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dilutive earnings per share
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Numerator:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Loss
|
|
$
|
(2,078
|
)
|
|
$
|
(40,308
|
)
|
|
$
|
(2,127
|
)
|
|
$
|
(44,394
|
)
|
Deemed capital contribution on extinguishment of preferred stock
|
|
|
31,480
|
|
|
|
-
|
|
|
|
31,480
|
|
|
|
-
|
|
Net income (loss) available to common stockholders
|
|
$
|
29,402
|
|
|
$
|
(40,308
|
)
|
|
$
|
29,353
|
|
|
$
|
(44,394
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Denominator:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average basic shares outstanding,
|
|
|
3,060,455
|
|
|
|
1,506,221
|
|
|
|
2,883,160
|
|
|
|
1,506,055
|
|
Weighted average effect of dilutive securities
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Employee stock options
|
|
|
1,646
|
|
|
|
-
|
|
|
|
684
|
|
|
|
-
|
|
Convertible preferred stock
|
|
|
123,482
|
|
|
|
-
|
|
|
|
259,601
|
|
|
|
-
|
|
Restricted stock units
|
|
|
7,644
|
|
|
|
-
|
|
|
|
3,577
|
|
|
|
-
|
|
Weighted average diluted shares
outstanding
|
|
|
3,193,227
|
|
|
|
1,506,221
|
|
|
|
3,147,022
|
|
|
|
1,506,055
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings per diluted share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Loss
|
|
$
|
(0.65
|
)
|
|
$
|
(26.76
|
)
|
|
$
|
(0.68
|
)
|
|
$
|
(29.48
|
)
|
Deemed capital contribution on extinguishment of preferred stock
|
|
|
9.86
|
|
|
|
-
|
|
|
|
10.00
|
|
|
|
-
|
|
Net income (loss) available to common stockholders
|
|
$
|
9.21
|
|
|
$
|
(26.76
|
)
|
|
$
|
9.32
|
|
|
$
|
(29.48
|
)
|
Securities that could potentially dilute loss per share in the future that were included in the computation
of diluted loss per share at June 30, 2016 and June 30, 2015 are as follows:
|
|
As of June 30,
|
|
|
|
2016
|
|
|
2015
|
|
Convertible preferred stock
|
|
|
2,926
|
|
|
|
265,517
|
|
Warrants to purchase common stock
|
|
|
1,251,709
|
|
|
|
40,516
|
|
Non-vested restricted stock awards
|
|
|
-
|
|
|
|
2,368
|
|
Non-vested restricted stock units
|
|
|
59,256
|
|
|
|
-
|
|
Options to purchase common stock
|
|
|
289,380
|
|
|
|
265,721
|
|
Total
|
|
|
1,603,271
|
|
|
|
574,122
|
|
Recent Accounting Pronouncements
In January 2016, the Financial Accounting
Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-01,
Recognition and Measurement
of Financial Assets and Financial Liabilities
. ASU 2016-01 requires equity investments to be measured at fair value with
changes in fair value recognized in net income; simplifies the impairment assessment of equity investments without readily determinable
fair values by requiring a qualitative assessment to identify impairment; eliminates the requirement for public business entities
to disclose the methods and significant assumptions used to estimate the fair value that is required to be disclosed for financial
instruments measured at amortized cost on the balance sheet; requires public business entities to use the exit price notion when
measuring the fair value of financial instruments for disclosure purposes; requires an entity to present separately in other comprehensive
income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit
risk when the entity has elected to measure the liability at fair value in accordance with the fair value option for financial
instruments; requires separate presentation of financial assets and financial liabilities by measurement category and form of financial
assets on the balance sheet or the accompanying notes to the financial statements; and clarifies that an entity should evaluate
the need for a valuation allowance on a deferred tax asset related to available-for-sale securities in combination with the entity’s
other deferred tax assets. ASU 2016-01 is effective for financial statements issued for fiscal years beginning after December
15, 2017, and interim periods within those fiscal years. The Company is currently evaluating the impact ASU 2016-01 will have
on its condensed consolidated financial statements.
In February 2016, the FASB issued ASU 2016-02,
Leases (Topic 842)
, which supersedes FASB ASC Topic 840,
Leases (Topic 840)
and provides principles for the recognition,
measurement, presentation and disclosure of leases for both lessees and lessors. The new standard requires lessees to apply a dual
approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively
a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective
interest method or on a straight-line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use
asset and a lease liability for all leases with a term of greater than twelve months regardless of classification. Leases with
a term of twelve months or less will be accounted for similar to existing guidance for operating leases. The standard is effective
for annual and interim periods beginning after December 15, 2018, with early adoption permitted upon issuance. The adoption of
this standard is not expected to have a material impact on the Company’s condensed consolidated financial position and results
of operations.
In March 2016, the FASB issued ASU 2016-08,
Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations
. The purpose of ASU 2016-08 is to
clarify the implementation of guidance on principal versus agent considerations. The amendments in ASU 2016-08 are effective for
interim and annual reporting periods beginning after December 15, 2017. The Company is currently assessing the impact of ASU 2016-08
on the condensed consolidated financial statements and related disclosures.
In March 2016, the FASB issued ASU No.
2016-09,
Compensation-Stock Compensation (Topic 718), Improvements to Employee Share-Based Payment Accounting
. Under ASU
No. 2016-09, companies will no longer record excess tax benefits and certain tax deficiencies in additional paid-in capital (“APIC”).
Instead, they will record all excess tax benefits and tax deficiencies as income tax expense or benefit in the income statement
and the APIC pools will be eliminated. In addition, ASU No. 2016-09 eliminates the requirement that excess tax benefits be realized
before companies can recognize them. ASU No. 2016-09 also requires companies to present excess tax benefits as an operating activity
on the statement of cash flows rather than as a financing activity. Furthermore, ASU No. 2016-09 will increase the amount an employer
can withhold to cover income taxes on awards and still qualify for the exception to liability classification for shares used to
satisfy the employer’s statutory income tax withholding obligation. An employer with a statutory income tax withholding obligation
will now be allowed to withhold shares with a fair value up to the amount of taxes owed using the maximum statutory tax rate in
the employee’s applicable jurisdiction(s). ASU No. 2016-09 requires a company to classify the cash paid to a tax authority
when shares are withheld to satisfy its statutory income tax withholding obligation as a financing activity on the statement of
cash flows. Under current U.S. GAAP, it was not specified how these cash flows should be classified. In addition, companies will
now have to elect whether to account for forfeitures on share-based payments by (1) recognizing forfeitures of awards as they occur
or (2) estimating the number of awards expected to be forfeited and adjusting the estimate when it is likely to change, as is currently
required. The amendments of this ASU are effective for reporting periods beginning after December 15, 2016, with early adoption
permitted but all of the guidance must be adopted in the same period. The Company is currently assessing the impact that ASU No.
2016-09 will have on its condensed consolidated financial statements.
In April 2016, the FASB issued ASU No.
2016-10,
Revenue from Contracts with Customer
. The new guidance is an update to ASC 606 and provides clarity on:
identifying performance obligations and licensing implementation. For public companies, ASU No. 2016-10 is effective for annual
periods, including interim periods within those annual periods, beginning after December 15, 2016. The Company is currently evaluating
the impact that ASU No. 2016-10 will have on its condensed consolidated financial statements.
In June 2016, the FASB issued ASU No. 2016-13,
Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments
. ASU No. 2016-13 requires
that expected credit losses relating to financial assets measured on an amortized cost basis and available-for-sale debt securities
be recorded through an allowance for credit losses. ASU No. 2016-13 limits the amount of credit losses to be recognized for
available-for-sale debt securities to the amount by which carrying value exceeds fair value and also requires the reversal of previously
recognized credit losses if fair value increases. The new standard will be effective on January 1, 2020. Early adoption will be
available on January 1, 2019. The Company is currently evaluating the effect that the updated standard will have on its condensed
consolidated financial statements and related disclosures.
Note 4. Intangible Assets
Patent Portfolio and Patent Rights
The Company’s intangible assets with
finite lives consist of its patents and patent rights. For all periods presented, all of the Company’s identifiable intangible
assets were subject to amortization. The gross carrying amounts related to acquired intangible assets as of June 30, 2016 are as
follows ($ in thousands):
|
|
Net Carrying Amount
|
|
|
Weighted average
amortization period
(years)
|
|
Patent Portfolios and Patent Rights at
December 31, 2015, net
|
|
$
|
9,799
|
|
|
|
4.63
|
|
Amortization expenses
|
|
|
(1,062
|
)
|
|
|
|
|
Patent Portfolios and Patent Rights at
June 30, 2016, net
|
|
$
|
8,737
|
|
|
|
4.14
|
|
The amortization expenses related to acquired
intangible assets for the three and six months ended June 30, 2016 and 2015 are as follows ($ in thousands):
|
|
For the Three Months Ended June 30,
|
|
|
For the Six Months Ended June 30,
|
|
Date Acquired and Description
|
|
2016
|
|
|
2015
|
|
|
2016
|
|
|
2015
|
|
7/24/13 - Rockstar patent portfolio
|
|
$
|
26
|
|
|
$
|
117
|
|
|
$
|
52
|
|
|
$
|
233
|
|
9/10/13 - North South patent portfolio
|
|
|
8
|
|
|
|
32
|
|
|
|
15
|
|
|
|
64
|
|
12/31/13 - Rockstar patent portfolio
|
|
|
497
|
|
|
|
2,301
|
|
|
|
995
|
|
|
|
4,575
|
|
|
|
$
|
531
|
|
|
$
|
2,450
|
|
|
$
|
1,062
|
|
|
$
|
4,872
|
|
The future amortization of these intangible
assets was based on the adjusted carrying amount. Future amortization of all patents is as follows ($ in thousands):
|
|
Rockstar
|
|
|
North South
|
|
|
Rockstar
|
|
|
|
|
|
|
Portfolio
|
|
|
Portfolio
|
|
|
Portfolio
|
|
|
|
|
|
|
Acquired
|
|
|
Acquired
|
|
|
Acquired
|
|
|
Total
|
|
|
|
24-Jul-13
|
|
|
10-Sep-13
|
|
|
31-Dec-13
|
|
|
Amortization
|
|
Six Months Ended December 31, 2016
|
|
$
|
52
|
|
|
$
|
16
|
|
|
$
|
1,004
|
|
|
$
|
1,072
|
|
Year Ended December 31, 2017
|
|
|
104
|
|
|
|
30
|
|
|
|
1,995
|
|
|
|
2,129
|
|
Year Ended December 31, 2018
|
|
|
104
|
|
|
|
31
|
|
|
|
1,995
|
|
|
|
2,130
|
|
Year Ended December 31, 2019
|
|
|
104
|
|
|
|
31
|
|
|
|
1,995
|
|
|
|
2,130
|
|
Year Ended December 31, 2020
|
|
|
104
|
|
|
|
31
|
|
|
|
995
|
|
|
|
1,130
|
|
Thereafter
|
|
|
110
|
|
|
|
36
|
|
|
|
-
|
|
|
|
146
|
|
Total
|
|
$
|
578
|
|
|
$
|
175
|
|
|
$
|
7,984
|
|
|
$
|
8,737
|
|
Equitable Agreement
In March 2016, the Company entered into
an agreement (which was subsequently amended) with Equitable IP Corporation (“Equitable”) to facilitate the monetization
of the Company’s patents (the “Monetization Agreement”). Pursuant to the Monetization Agreement, the Company
will work together with Equitable to develop and revise the Company’s ongoing litigation plan. Under the Monetization Agreement,
Equitable is obligated to use its best, commercially reasonable efforts to monetize the Company’s patents. To that end, Equitable
has agreed to file eight additional litigations by September 30, 2016. The Company will share net monetization revenue derived
from all monetization activity equally with Equitable. To facilitate the litigation plan, approximately 186 of over 330 of the
Company’s patents and applications have been assigned to Equitable, which will pay all maintenance and prosecution fees going
forward. If Equitable fails to timely file the eight litigations, then the Company has the option to reacquire the assigned patents
at no cost. No assigned patents may be transferred by Equitable to a third party without the Company’s consent. In the event
that all terms of the Monetization Agreement are met by December 2017, the Company will further assign approximately 140 additional
patents and applications to Equitable for monetization. The Company has retained a grant-back license to practice all transferred
patents.
The Company concluded that the Monetization
Agreement did not constitute a sale of the patents. The Company’s retention of the right to use the patents, the requirement
for the Company’s consent to any sale, and the significant economic benefits the Company retained with respect to the litigation,
licensing, and sale proceeds, did not meet the sale of patent criteria. The Monetization Agreement has been treated as an
agreement to outsource its licensing activities to an outside servicer, for contingent fees based on the success of the servicer’s
efforts. As such, the Company will not remove the patents from its condensed consolidated balance sheet, and will record its share
of litigation, licensing, and sales proceeds, if any, when those proceeds are received, or when due if the other revenue recognition
criteria are met under ASC 605,
Revenue Recognition
.
Note 5. Fair Value of Financial Assets and Liabilities
Financial instruments, including cash and
cash equivalents, accounts and other receivables, accounts payable and accrued liabilities are carried at cost, which management
believes approximates fair value due to the short-term nature of these instruments. The Company measures the fair value of financial
assets and liabilities based on the exchange price that would be received for an asset or paid to transfer a liability (an exit
price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants
on the measurement date. The Company maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring
fair value.
The Company uses three levels of inputs
that may be used to measure fair value:
Level 1 - quoted prices in active
markets for identical assets or liabilities
Level 2 - quoted prices for
similar assets and liabilities in active markets or inputs that are observable
Level 3 - inputs that are unobservable
(for example, cash flow modeling inputs based on assumptions)
The following table presents the Company’s
assets and liabilities that are measured at fair value at June 30, 2016 and December 31, 2015 ($ in thousands):
|
|
Fair value measured at June 30, 2016
|
|
|
|
Total carrying value
at June 30,
|
|
|
Quoted prices in
active markets
|
|
|
Significant other
observable inputs
|
|
|
Significant
unobservable inputs
|
|
|
|
2016
|
|
|
(Level 1)
|
|
|
(Level 2)
|
|
|
(Level 3)
|
|
Assets
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Marketable securities - corporate bonds
|
|
$
|
5,671
|
|
|
$
|
-
|
|
|
$
|
5,671
|
|
|
$
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair value of warrant liabilities
|
|
$
|
1,928
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
1,928
|
|
|
|
Fair value measured at
December 31, 2015
|
|
|
|
Total carrying value
at December 31,
|
|
|
Quoted prices in
active markets
|
|
|
Significant other
observable inputs
|
|
|
Significant
unobservable inputs
|
|
|
|
2015
|
|
|
(Level 1)
|
|
|
(Level 2)
|
|
|
(Level 3)
|
|
Assets
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Marketable securities - mutual funds
|
|
$
|
3,392
|
|
|
$
|
3,392
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair value of warrant liabilities
|
|
$
|
2,959
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
2,959
|
|
There were no transfers between Level 1,
2 or 3 during the six months ended June 30, 2016.
Level 3 Valuation Techniques
Level 3 financial liabilities consist of
the warrant liabilities for which there is no current market for these securities such that the determination of fair value requires
significant judgment or estimation. Changes in fair value measurements categorized within Level 3 of the fair value hierarchy are
analyzed each period based on changes in estimates or assumptions and recorded as appropriate.
A significant decrease in the volatility
or a significant decrease in the Company’s stock price, in isolation, would result in a significantly lower fair value measurement.
Changes in the values of the warrant liabilities are recorded in “fair value adjustments for warrant liabilities” in
the Company’s condensed consolidated statements of operations.
On July 21, 2015, the Company issued warrants
to purchase an aggregate of 370,263 shares of common stock (the “July 2015 Warrants”) to the investors in the July
2015 Financing. The July 2015 Warrants became exercisable on January 22, 2016 at an exercise price of $8.17 per share. The warrants
require, at the option of the holder, a net-cash settlement following certain fundamental transactions (as defined in the July
2015 Warrants) at the Company and therefore are classified as liabilities. The July 2015 Warrants have been recorded at their fair
value using the Black-Scholes valuation model, and will be recorded at their respective fair value at each subsequent balance sheet
date. This model incorporates transaction details such as the Company’s stock price, contractual terms, maturity, risk free
rates, as well as volatility.
On December 7, 2015, the Company issued
Series A warrants to purchase up to 1,052,624 shares of common stock and Series B warrants to purchase up to 842,099 shares of
common stock contained in December Offering. Series A Warrants have an exercise price of $3.80 per share and are exercisable at
any time between December 7, 2015 and May 6, 2016. 852,624 shares of Series A warrants expired on May 24, 2016, and no Series A
Warrants remain outstanding as of June 30, 2016. Series B Warrants have an exercise price of $4.75 per share and are exercisable
at any time between December 7, 2015 and December 6, 2020. The Warrants require the issuance of registered shares upon exercise,
do not expressly preclude an implied right to cash settlement and are therefore accounted for as derivative liabilities.
The Company classifies these derivative warrant liabilities on the condensed consolidated balance sheet as a current liability.
The Series A and Series B warrants have
been recorded at their fair value using the Black-Scholes valuation model, and will be recorded at their respective fair value
at each subsequent balance sheet date. This model incorporates transaction details such as the Company’s stock price, contractual
terms, maturity, risk free rates, as well as volatility.
A summary of quantitative information with
respect to the valuation methodology and significant unobservable inputs used for the Company’s warrant liabilities that
are categorized within Level 3 of the fair value hierarchy at the date of issuance and as of June 30, 2016 is as follows:
Date of valuation
|
|
June 30, 2016
|
|
Risk-free interest rate
|
|
|
0.45% - 1.01%
|
|
Expected volatility
|
|
|
100% - 173.11%
|
|
Expected life (in years)
|
|
|
0.33 - 4.56
|
|
Expected dividend yield
|
|
|
-
|
|
The risk-free interest rate was based on
rates established by the Federal Reserve. For the July 2015 Warrants, the expected volatility in the Black-Scholes model is based
on an expected volatility of 100% for both periods which represents the percentage required to be used when valuing the cash settlement
feature as contractually stated in the form of warrant. The general expected volatility is based on standard deviation of the Company’s
underlying stock price's daily logarithmic returns. The expected life of the warrants was determined by the expiration date of
the warrants. The expected dividend yield was based upon the fact that the Company has not historically paid dividends on its common
stock, and does not expect to pay dividends on its common stock in the future.
The following table sets forth a summary
of the changes in the fair value of the Company’s Level 3 financial liabilities that are measured at fair value on a recurring
basis as of June 30, 2016 and December 31, 2015 ($ in thousands):
|
|
Fair Value of Level 3 financial liabilities
|
|
|
|
June 30,
2016
|
|
|
June 30,
2015
|
|
Beginning balance
|
|
$
|
2,959
|
|
|
$
|
-
|
|
Recognition of warrant liabilities
|
|
|
-
|
|
|
|
-
|
|
Fair value adjustment of warrant liabilities
|
|
|
(1,031
|
)
|
|
|
-
|
|
Ending balance
|
|
$
|
1,928
|
|
|
$
|
-
|
|
Note 6. Stockholders’ Equity and Redeemable Convertible
Preferred Stock
Restated Certificate of Incorporation
On March 4, 2016, the Company implemented
a Reverse Stock Split with a ratio of 1-for-19. The par value and other terms of the common stock were not affected by the Reverse
Stock Split. In addition, the amendment to the Company’s certificate of incorporation that effected the Reverse Stock Split
simultaneously reduced the number of authorized shares of Common Stock from 200,000,000 to 100,000,000 (see Note 1).
Preferred Stock
The Company had designated separate series
of its capital stock as of June 30, 2016 and December 31, 2015 as summarized below:
|
|
Number of Shares Issued
|
|
|
|
|
|
|
|
|
and Outstanding as of
|
|
|
|
|
|
|
|
|
June 30,
2016
|
|
|
December 31,
2015
|
|
|
Par Value
|
|
|
Conversion Ratio
|
Series "A"
|
|
|
-
|
|
|
|
-
|
|
|
$
|
0.0001
|
|
|
N/A
|
Series "C"
|
|
|
-
|
|
|
|
-
|
|
|
|
0.0001
|
|
|
0.05:1
|
Series “D"
|
|
|
4,725
|
|
|
|
4,725
|
|
|
|
0.0001
|
|
|
0.53:1
|
Series “D-1"
|
|
|
834
|
|
|
|
834
|
|
|
|
0.0001
|
|
|
0.53:1
|
Series “F-1"
|
|
|
-
|
|
|
|
-
|
|
|
|
0.0001
|
|
|
0.05:1
|
Series “H"
|
|
|
-
|
|
|
|
381,967
|
|
|
|
0.0001
|
|
|
0.53:1
|
Series “I”
|
|
|
-
|
|
|
|
-
|
|
|
|
0.0001
|
|
|
1.05:1
|
Series “J”
|
|
|
-
|
|
|
|
-
|
|
|
|
0.0001
|
|
|
0.05:1
|
Series “K”
|
|
|
-
|
|
|
|
1,240
|
|
|
|
0.0001
|
|
|
263.16:1
|
Series H Convertible Preferred Stock
On December 31, 2013, the Company designated
459,043 shares of preferred stock as Series H Preferred Stock. On December 31, 2013, the Company issued approximately
$38.3 million of Series H Preferred Stock (or 459,043 shares) to Rockstar. Each share of Series H Preferred Stock is
convertible into ten-nineteenths of a share of Common Stock and has a stated value of $83.50. The conversion ratio is
subject to adjustment in the event of stock splits, stock dividends, combination of shares and similar recapitalization transactions.
The Company is prohibited from effecting the conversion of the Series H Preferred Stock to the extent that, as a result
of such conversion, the holder beneficially owns more than 4.99% (which may be increased to 9.99% and subsequently to 19.99%, each
upon 61 days’ written notice), in the aggregate, of issued and outstanding shares of Common Stock calculated immediately
after giving effect to the issuance of shares of Common Stock upon the conversion of the Series H Preferred Stock. Holders
of the Series H Preferred Stock shall be entitled to vote on all matters submitted to the Company’s stockholders and shall
be entitled to the number of votes equal to the number of shares of Common Stock into which the shares of Series H Preferred Stock
are convertible, subject to applicable beneficial ownership limitations. The Series H Preferred Stock provides a liquidation
preference of $83.50 per share. The shares of Series H Preferred Stock were not immediately convertible and did not
possess any voting rights until such a time as the Company had obtained stockholder approval of the issuance, pursuant to NASDAQ
Listing Rule 5635. On April 16, 2014, the Company obtained the required stockholder approval and, as a result, all
outstanding shares of Series H Preferred Stock are convertible and possess voting rights in accordance with its terms. On
May 28, 2014, 20,000 shares of Series H Preferred Stock were converted into 10,526 shares of Common Stock.
In January 2015, Rockstar transferred its
remaining outstanding Series H Preferred Stock to RPX Clearinghouse LLC, an affiliate of RPX, but retained certain recovery benefits
set forth in the 2013 Patent Purchase Agreement between the Company and Rockstar.
According to the RPX License Agreement
disclosed in Note 7, on November 23, 2015, RPX transferred to the Company for cancellation 57,076 shares of Series H Preferred
Stock then held by RPX, having a total carrying amount of $4,765,846 at the time the stock was issued to Rockstar.
In connection with a second, separate,
licensing agreement, on May 23, 2016, RPX transferred to the Company for cancellation of 100% of the remaining 381,967 shares of
Series H Preferred Stock held by RPX, having a total carrying amount of $31,894,244 at the time the stock was issued to Rockstar
(see Note 7 for further details).
As of June 30, 2016, no shares of Series
H Preferred Stock remained issued and outstanding.
Series K Convertible Preferred Stock
On December 2, 2015, the Company designated
1,240 shares of preferred stock as Series K Preferred Stock. On December 7, 2015, the Company issued 1,240 shares of
Series K Preferred Stock in December 2015 Offering. Each share of Series K Preferred Stock is convertible into five
thousand-nineteenths of a share of Common Stock and has a stated value of $1,000. The conversion ratio is subject to
adjustment in the event of stock splits, stock dividends, combination of shares and similar recapitalization transactions. The
Series K Preferred does not generally have any voting rights but are convertible into shares of Common Stock. At no time may shares
of Series K Preferred Stock be converted if such conversion would cause the holder to hold in excess of 4.99% of the issued and
outstanding Common Stock, subject to an increase in such limitation up to 9.99% of the issued and outstanding Common Stock on 61
days’ written notice to the Company by such holder. The conversion ratio of the Series K Preferred Stock is subject
to adjustment in the event of stock splits, stock dividends, combination of shares and similar recapitalization transactions.
During the six months ended June 30, 2016, 1,240 shares of Series K Preferred Stock were converted into
326,315 shares of Common Stock. As of June 30, 2016, no shares of Series K Preferred Stock remained issued and outstanding.
Warrants
A summary of warrant activity for the six
months ended June 30, 2016 is presented below:
|
|
Warrants
|
|
|
Weighted Average
Exercise Price
|
|
|
Total Intrinsic
Value
|
|
|
Weighted Average
Remaining Contractual
Life
(in years)
|
|
Outstanding as of December 31, 2015
|
|
|
2,304,888
|
|
|
$
|
7.98
|
|
|
$
|
-
|
|
|
|
2.83
|
|
Exercised
|
|
|
(200,000
|
)
|
|
|
3.80
|
|
|
|
|
|
|
|
|
|
Expired
|
|
|
(853,179
|
)
|
|
|
|
|
|
|
|
|
|
|
-
|
|
Outstanding as of June 30, 2016
|
|
|
1,251,709
|
|
|
$
|
10.15
|
|
|
|
|
|
|
|
4.42
|
|
Exercisable as of June 30, 2016
|
|
|
1,251,709
|
|
|
$
|
10.15
|
|
|
$
|
-
|
|
|
|
4.42
|
|
During the quarter ended June 30, 2016, 200,000 Series A warrants with a weighted average exercise price
of $3.80 were exercised for cash of $760,000. No Series A warrants remain outstanding as of June 30, 2016.
Stock Options
Also approved by the Company’s Stockholders on February 26, 2016 was an amendment to the Company’s
2014 Equity Incentive Plan, which increased the number of shares of common stock authorized to be issued pursuant to the 2014 Plan
from 4,161,892 to 8,250,000 prior to effectuation of the 1:19 reverse stock split, proportionately reducing the total share authorization
under the plan to 434,210 shares.
During the second quarter ended June 30,
2016, pursuant to and subject to the available number of shares reserved under the 2014 Plan, the Company issued 19,735 options
to five of the Company’s directors. The aggregate grant date fair value of these options was approximately $31,000.
A summary of option activity under the Company’s employee
stock option plan for the six months ended June 30, 2016 is presented below:
|
|
Number of Shares
|
|
|
Weighted Average
Exercise Price
|
|
|
Total Intrinsic
Value
|
|
|
Weighted Average
Remaining Contractual
Life (in years)
|
|
Outstanding as of December 31, 2015
|
|
|
286,487
|
|
|
$
|
89.07
|
|
|
$
|
-
|
|
|
|
5.0
|
|
Employee options granted
|
|
|
19,735
|
|
|
|
1.98
|
|
|
|
7,894
|
|
|
|
4.8
|
|
Outstanding as of June 30, 2016
|
|
|
306,222
|
|
|
$
|
83.46
|
|
|
$
|
7,894
|
|
|
|
4.6
|
|
Options vested and expected to vest
|
|
|
306,222
|
|
|
$
|
83.46
|
|
|
$
|
7,894
|
|
|
|
4.6
|
|
Options vested and exercisable
|
|
|
294,384
|
|
|
$
|
86.72
|
|
|
$
|
3,948
|
|
|
|
4.6
|
|
A summary of option activity under the
Company’s non-employee stock option plan for the six months ended June 30, 2016 is presented below:
|
|
Number of
Shares
|
|
|
Weighted
Average
Exercise Price
|
|
|
Total Intrinsic
Value
|
|
|
Weighted Average
Remaining Contractual
Life (in years)
|
|
Outstanding as of December 31, 2015
|
|
|
2,893
|
|
|
$
|
98.07
|
|
|
$
|
-
|
|
|
|
5.4
|
|
Non-employee options granted
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Outstanding as of June 30, 2016
|
|
|
2,893
|
|
|
$
|
98.07
|
|
|
$
|
-
|
|
|
|
4.9
|
|
Options vested and expected to vest
|
|
|
2,893
|
|
|
$
|
98.07
|
|
|
$
|
-
|
|
|
|
4.9
|
|
Options vested and exercisable
|
|
|
2,893
|
|
|
$
|
98.07
|
|
|
$
|
-
|
|
|
|
4.9
|
|
Stock-based compensation associated with
the amortization of stock option expense was approximately $19,000 and $14,000 for the three months ended June 30, 2016 and 2015,
and was approximately $21,000 and $0.1 million for the six months ended June 30, 2016 and 2015, respectively. Unamortized
stock-based compensation expense amounted to approximately $14,000 at June 30, 2016, and will be amortized over 0.84 years.
Restricted Stock Awards
In December 2015, the Company entered into a consulting agreement with a third party for consulting services.
The Company agreed to pay the consultant $50,000 in shares of the Company’s common stock, which were issued in two equal
parts. The first $25,000 (8,771 shares) of restricted stock was issued in January 2016, and the second $25,000 (or 10,870 shares)
of restricted stock was issued in June 2016.
In December 2015, the Company determined
to pay each of Mr. Reiner and Mr. Dotson, in accordance with their respective employment agreements, $60,000 in shares of common
stock in respect of their performance for the 2015 fiscal year which, as of the closing price of December 21, 2015, would have
constituted a total of 42,106 shares. The shares were issued in March 2016.
On January 26, 2016, the Company issued
652 shares of restricted common stock to a third party for consulting services. The restricted stock award vested immediately.
The grant date fair value of restricted stock was $1,487.
On February 4, 2016, the Company entered
into a consulting agreement with a third party. The Company has agreed to pay the consultant three cash retainer payments for a
total of $70,000, and granted $100,000 in shares of restricted stock. On February 4, 2016, the Company issued 42,445 restricted
shares based on the average closing price for the 10 trading days immediately prior to February 4, 2016. The restricted stock award
vested immediately.
On February 26, 2016, the Company granted
each of two consultants 7,895 shares of restricted common stock for consulting services. The restricted stock award vested on March
31, 2016 based upon the closing price on February 26, 2016. The grant date fair value of each restricted stock award was $15,000,
respectively.
On June 22, 2016, the Company granted two
consultants 10,870 and 43,479 shares of restricted common stock for consulting services, respectively. The restricted stock award
vested immediately. The grant date fair value of restricted stock was $25,000 and $100,000, respectively.
A summary of the restricted stock award
activity for the six months ended June 30, 2016 is as follows:
|
|
Number of Units
|
|
|
Weighted Average
Grant Day Fair Value
|
|
Nonvested at December 31, 2015
|
|
|
-
|
|
|
$
|
-
|
|
Granted
|
|
|
164,113
|
|
|
|
2.20
|
|
Vested
|
|
|
(164,113
|
)
|
|
|
2.20
|
|
Nonvested at June 30, 2016
|
|
|
-
|
|
|
$
|
-
|
|
Restricted Stock Units
On May 20, 2016, Mr. Hayes was granted an award of restricted stock units totaling 118,512 shares of common
stock, which will vest upon the achievement of agreed upon performance milestones.
A summary of the restricted stock award
activity for the six months ended June 30, 2016 is as follows:
|
|
Number of Units
|
|
|
Weighted Average
Grant Day Fair Value
|
|
Nonvested at December 31, 2015
|
|
|
-
|
|
|
$
|
-
|
|
Granted
|
|
|
118,512
|
|
|
|
2.20
|
|
Vested
|
|
|
-
|
|
|
|
-
|
|
Nonvested at June 30, 2016
|
|
|
118,512
|
|
|
$
|
2.20
|
|
As of June 30,
2016, the Company had unrecognized stock-based compensation expense related to restricted stock unit awards of approximately $0.1
million, which is expected to be recognized over the remaining weighted-average vesting period of 0.5 years.
Stock-based Compensation
Stock-based compensation for the six months
ended June 30, 2016 and 2015 was comprised of the following ($ in thousands):
|
|
For the Three Months Ended June 30,
|
|
|
For the Six Months Ended June 30,
|
|
|
|
2016
|
|
|
2015
|
|
|
2016
|
|
|
2015
|
|
Employee restricted stock awards
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
11
|
|
Employee restricted stock units
|
|
|
23
|
|
|
|
-
|
|
|
|
23
|
|
|
|
-
|
|
Employee stock option awards
|
|
|
19
|
|
|
|
14
|
|
|
|
21
|
|
|
|
90
|
|
Non-employee restricted stock awards
|
|
|
125
|
|
|
|
33
|
|
|
|
255
|
|
|
|
33
|
|
Total compensation expense
|
|
$
|
167
|
|
|
$
|
47
|
|
|
$
|
299
|
|
|
$
|
134
|
|
Note 7. May RPX License Agreement
On November 23, 2015, the Company and RPX
Corporation (“RPX”) entered into a Patent License Agreement (the “RPX License Agreement”) under which the
Company granted RPX the right to sublicense various patent license rights to certain RPX members. The consideration to the Company
included: (i) the transfer to the Company for cancellation of its remaining outstanding Series I Redeemable Convertible Preferred
Stock (the “Series I Preferred Stock”), as to which a $5,000,000 mandatory redemption payment would have been due from
the Company on or by December 31, 2015; (ii) the transfer to the Company for cancellation of 13%, or 57,076 shares, of its Series
H Convertible Preferred Stock (the “Series H Preferred Stock”) then held by RPX, having a total carrying amount of
$4,765,846 at the time the stock was issued to Rockstar; (iii) cancellation of the only outstanding security interest on 101 of
the Company’s patents and patent applications that originated at Nortel Networks (“Nortel”) and were purchased
by the Company from Rockstar, which security interest had previously been transferred to RPX by Rockstar (“RPX Security Interest”);
and (iv) $300,000 in cash to the Company. While the license granted to RPX is non-exclusive and the duration of the license is
for the life of the patents, the Company’s ongoing obligations in the arrangement is to provide certain specific RPX licensors
with a non-exclusive license to any new patents that may be acquired by or exclusively licensed to the Company during the two-year
period following the effective date of the agreement. Therefore, the Company will recognize $0.6 million revenue ratably over the
two-year period that it is obligated to provide these RPX licensees with licenses to such new patents. During the three and six
months ended June 30, 2016, the Company recorded approximately $72,000 and $144,000, respectively, in revenue related to the amortization
of the license.
On May 23, 2016, the Company, and RPX,
entered into a second, separate, Patent License Agreement (the “RPX License”) under which the Company granted RPX the
right to sublicense various patent rights only to current RPX clients (as of May 23, 2016). In exchange for the rights granted
by the Company under the RPX License, the Company received the following consideration: (i) a cash payment made to the Company
in May 2016 in the amount of $4,355,000; and (ii) cancellation of 100% of the remaining 381,967 shares of the Company’s outstanding
Series H Convertible Preferred Stock currently held by RPX, having a total carrying amount of $31,894,244 at the time the stock
was issued to Rockstar Consortium US LP (“Rockstar”).
In consideration of the above, the Company
granted RPX the rights to grant to its current clients: (i) a fully paid portfolio license, to the extent such parties did not
already have licenses to the Company’s patents; (ii) a covenant-not-to-sue current RPX clients for supply of chipsets; (iii)
a standstill of litigation involving any patents acquired in the next five years (“Standstill”).
The Company also granted to Alcatel-Lucent
a license to the portfolio acquired from the Harris Corporation.
Under a separate agreement between the
Company and RPX, the Company granted RPX the ability to grant to VTech Telecommunications Ltd. (“VTech”) a sublicense
for a fully paid portfolio license in exchange for an additional $20,000 in cash consideration.
The license granted under the terms of
the RPX License described herein does not extend to entities/companies that are not clients of RPX and provide chipsets or other
hardware to current RPX clients.
The carrying value of Series H
Convertible Preferred Stock on the extinguishment date was estimated at approximately $31.9 million. The fair value on the
same date was estimated at approximately $414,000 based upon equivalent common shares that the Series H Convertible Preferred
Stock could have converted into at the closing price on May 23, 2016. This resulted in the Company receiving cash from RPX of
$4.4 million, a deemed dividend of approximately $31.5 million, short term deferred revenue $1.1 million and long
term deferred revenue of $3.7 million. The deferred revenue will be amortized over a 5-year service period as the RPX
License includes a standstill agreement which requires Spherix to provide the licensee with the right to use any future
acquired patents for five years. During the three and six months ended June 30, 2016, the Company recorded approximately
$105,000, in revenue related to the amortization of the license.
ASC 260-10-S99-2,
Effect on the Calculation
of Earnings per Share for the Redemption or Induced Conversion of Preferred Stock
, requires the gain or loss on extinguishment
of equity-classified preferred stock to be included in net income per common stockholder used to calculate earnings per share (similar
to the treatment of dividends paid on preferred stock). The difference between (1) the fair value of the consideration transferred
to the holders of the preferred stock and (2) the carrying amount of the preferred stock (net of issuance costs) is subtracted
from (or added to) net income to arrive at income available to common stockholders in the calculation of earnings per share.
Note 8. Commitments and Contingencies
Legal Proceedings
In the ordinary course of business, the
Company actively pursues legal remedies to enforce its intellectual property rights and to stop unauthorized use of our technology. From
time to time, the Company may be involved in various claims and counterclaims and legal actions arising in the ordinary course
of business. There were no pending material claims or legal matters as of the date of this report other than the following
matters:
Spherix Incorporated v. VTech Telecommunications
Ltd. et al., Case No. 3:13-cv-03494-M, in the United States District Court for the Northern District of Texas
On August 30, 2013, the Company initiated
litigation against VTech Telecommunications Ltd. and VTech Communications, Inc. (collectively “VTech”) in
Spherix
Incorporated v. VTech Telecommunications Ltd. et al
, Case No. 3:13-cv-03494-M, in the United States District Court for the
Northern District of Texas (“the Court”) for infringement of U.S. Patent Nos. 5,581,599; 5,752,195; 5,892,814; 6,614,899;
and 6,965,614 (collectively, the “Asserted Patents”). The complaint alleges that VTech has manufactured, sold, offered
for sale and/or imported technology that infringes the Asserted Patents. The Company is seeking relief in the form of a finding
of infringement of the Asserted Patents, an accounting of all damages sustained by the Company as a result of VTech’s infringement,
actual damages, enhanced damages under 35 U.S.C. Section 284, attorney’s fees and costs. On November 11, 2013, VTech filed
its Answer with counterclaims requesting a declaration that the Asserted Patents are non-infringed and invalid. On December 5,
2013, the Company filed its Answer to the counterclaims, in which the Company denied that the Asserted Patents were non-infringed
and invalid. On May 22, 2014, the Court entered a Scheduling Order for the case setting trial to begin on January 11, 2016. On
June 3, 2014, in an effort to narrow the case, the parties filed a stipulation dismissing without prejudice all claims and counterclaims
related to U.S. Patent No. 5,752,195. On September 4, 2014, VTech Communications, Inc., together with Uniden America Corporation,
filed a request for
inter partes
review (“IPR”) of two of the Asserted Patents in the United States Patent and
Trademark Office. On March 3, 2015, the Patent Trial and Appeal Board (“PTAB”) entered decisions instituting, on limited
grounds, IPR proceedings regarding a portion of the claims for the two Spherix patents. The PTAB also suggested an accelerated
IPR schedule to culminate in an oral hearing on or about September 28, 2015. The PTAB held a conference call with the parties on
March 17, 2015 to finalize the IPR schedule. On October 27, 2014, the Court held a Technology Tutorial Hearing for the educational
benefit of the Court. The
Markman
hearing was held on November 21 and 26, 2014. Both the Technology Tutorial and the
Markman
hearing were held jointly with the
Spherix Incorporated v. Uniden Corporation et al.
case (see below). On March
19, 2015, the Court issued its
Markman
order, construing a total of 13 claim terms that had been disputed by the parties.
On April 2, 2015, the Company filed an Amended Complaint with Jury Demand and the parties filed a Settlement Conference Report
informing the Court that the parties have not yet resumed settlement negotiations. The Court has ordered the parties to hold a
settlement conference not later than December 28, 2015. On April 15, 2015, the Company filed a Motion to Compel Production of Technical
Documents against Defendants. On April 20, 2015, the Company filed an Opposed Motion for Leave to Serve Supplemental Infringement
Contentions. Also on April 20, 2015, Defendants filed their Amended Answer to the Company’s Amended Complaint with their
counterclaims. On May 1, 2015, the Company filed its Answer to the counterclaims. On May 5, 2015, the parties filed a Joint Stipulation
and Motion to Modify the Scheduling Order. On May 6, 2015, the Court entered the Stipulation, in which the Court estimated the
trial date to occur in July of 2016 and ordered the parties to be ready for trial on or after June 22, 2016. The Company’s
patent owner’s response to the petition in the IPR was timely filed on May 26, 2015. On September 28, 2015, the hearing in
the IPR proceedings was held before the PTAB. On October 9, 2015, the parties filed a Joint Motion to stay the litigation pending
the issuance of the PTAB’s final written decisions in the IPR proceedings. On October 13, 2015, the Court granted the stay
and administratively closed the case until the PTAB issues its final written decisions. On February 3, 2016, the PTAB issued its
final decisions in the IPR proceedings, finding invalid eight of the 15 asserted claims of U.S. Patent No. 5,581,599 (“the
’599 Patent”) and all asserted claims of U.S. Patent No. 6,614,899. The Company’s deadline to file a Notice of
Appeal of the PTAB’s decision to the United States Court of Appeals for the Federal Circuit (“Federal Circuit”)
is April 6, 2016. On February 29, 2016, at the parties’ joint request, the Court ordered that the stay of the case remain
in effect for 30 days so the parties may work to resolve the case without further Court intervention. The Court also ordered the
parties to file an updated status report on or before March 31, 2016 advising the Court of their progress toward resolving this
litigation without further Court intervention and whether it is appropriate to reopen the case and lift the stay. The parties timely
filed a Joint Status Report on March 31, 2016, in which they requested that the stay remain in effect pending the Federal Circuit
issuing a ruling in connection with the appeal of IPR2014-01431 relating to the ‘599 Patent. On April 1, 2016, the Company
filed its Patent Owner’s Notice of Appeal in IPR2014-01431. On April 11, 2016, the Court granted the parties’ motion
to continue the stay. On May 23, 2016, we granted RPX Corporation the ability to grant to VTech a sublicense for a fully paid portfolio
license, including a license to the Asserted Patents. On June 15, 2016, the parties filed a joint motion to dismiss with prejudice
all claims and counterclaims asserted in the case. On June 21, 2016, the Court granted the joint motion to dismiss. On June 17,
2016, we filed a motion with the Federal Circuit requesting that VTech be withdrawn as a party to the appeal. On June 21, 2016,
the Federal Circuit granted the motion to withdraw VTech as a party.
Spherix Incorporated v. Uniden Corporation
et al., Case No. 3:13-cv-03496-M, in the United States District Court for the Northern District of Texas
On August 30, 2013, the Company initiated
litigation against Uniden Corporation and Uniden America Corporation (collectively “Uniden”) in
Spherix Incorporated
v. Uniden Corporation et al
, Case No. 3:13-cv-03496-M, in the United States District Court for the Northern District of Texas
(“the Court”) for infringement of U.S. Patent Nos. 5,581,599; 5,752,195; 6,614,899; and 6,965,614 (collectively, the
“Asserted Patents”). The complaint alleges that Uniden has manufactured, sold, offered for sale and/or imported technology
that infringes the Asserted Patents. The Company is seeking relief in the form of a finding of infringement of the Asserted Patents,
an accounting of all damages sustained by the Company as a result of Uniden’s infringement, actual damages, enhanced damages
under 35 U.S.C. Section 284, attorney’s fees and costs. On April 15, 2014, Uniden filed its Answer with counterclaims requesting
a declaration that the patents at issue are non-infringed and invalid. On April 28, 2014, the Company filed its Answer to the counterclaims,
in which the Company denied that the patents at issue were non-infringed and invalid. On May 22, 2014, the Court entered a scheduling
order for the case setting trial to begin on February 10, 2016. On June 3, 2014, in an effort to narrow the case, the parties filed
a stipulation dismissing without prejudice all claims and counterclaims related to U.S. Patent No. 5,752,195. On September 4, 2014,
Uniden America Corporation, together with VTech Communications, Inc., filed a request for
inter partes
review (“IPR”)
of two of the Asserted Patents in the United States Patent and Trademark Office. On March 3, 2015, the PTAB entered decisions instituting,
on limited grounds, IPR proceedings regarding a portion of the claims for the two Spherix patents. The PTAB also suggested an accelerated
IPR schedule to culminate in an oral hearing on September 28, 2015. The PTAB held a conference call with the parties on March 17,
2015 to finalize the IPR schedule. On October 27, 2014, the Court held a Technology Tutorial Hearing for the educational benefit
of the Court. The
Markman
hearing was held on November 21 and 26, 2014, with both hearings occurring jointly with the
Spherix Incorporated v. VTech Telecommunications Ltd. et al.
case (see above). On March 19, 2015, the Court issued its
Markman
order, construing a total of 13 claim terms that had been disputed by the parties. On April 2, 2015, the Company filed its Amended
Complaint with Jury Demand and the parties filed a Settlement Conference Report informing the Court that the parties have not yet
resumed settlement negotiations. The Court has ordered the parties to hold a settlement conference not later than January 20, 2016.
On April 9, 2015, the parties filed a Joint Motion to Modify Patent Scheduling Order. On April 10, 2015, the Court granted the
Motion. On April 20, 2015, Defendants filed their Amended Answer to the Company’s Amended Complaint with their counterclaims.
On May 1, 2015, the Company filed its Answer to the counterclaims. The Company’s patent owner’s response to the petition
in the IPR was timely filed on May 26, 2015. On July 9, 2015, the Court issued a modified Scheduling Order setting the Final Pretrial
Conference for February 2, 2016 and confirming the Trial Date beginning February 20, 2016. On September 9, 2015, the parties jointly
filed a motion to stay the case pending the decision in the two IPR proceedings. On September 10, 2015, the Court stayed the case
and ordered the parties to file a status report within 10 days of the Patent Office issuing its decision in the IPR proceedings.
On October 13, 2015, the Court ordered the case administratively closed until the PTAB issues its final written decisions. On February
3, 2016, the PTAB issued its final decisions in the IPR proceedings, finding invalid eight of the 15 asserted claims of U.S. Patent
No. 5,581,599 (“the ’599 Patent”) and all asserted claims of U.S. Patent No. 6,614,899. The Company’s deadline
to file a Notice of Appeal of the PTAB’s decision to the United States Court of Appeals for the Federal Circuit (“Federal
Circuit”) is April 6, 2016. On February 29, 2016, at the parties’ joint request, the Court ordered that the stay of
the case remain in effect for 30 days so the parties may work to resolve the case without further Court intervention. The Court
also ordered the parties to file an updated status report on or before March 31, 2016 advising the Court of their progress toward
resolving this litigation without further Court intervention and whether it is appropriate to reopen the case and lift the stay.
The parties timely filed a Joint Status Report on March 31, 2016, in which they requested that the stay remain in effect pending
the Federal Circuit issuing a ruling in connection with the appeal of IPR2014-01431 relating to the ‘599 Patent. On April
1, 2016, the Company filed its Patent Owner’s Notice of Appeal in IPR2014-01431. On April 11, 2016, the Court granted the
parties’ motion to continue the stay. On July 18, 2016, we timely filed our Opening Brief in our appeal to the Federal Circuit.
Uniden’s reply brief is due on August 29, 2016.
Spherix Incorporated v. Cisco Systems
Inc., Case No. 1:14-cv-00393-SLR, in the United States District Court for the District of Delaware.
On March 28, 2014, the Company initiated
litigation against Cisco Systems Inc. (“Cisco”) in Spherix Incorporated v. Cisco Systems Inc., Case No. 1:14-cv-00393-
SLR, in the United States District Court for the District of Delaware for infringement of U.S. Patent Nos. RE40467; 6,697,325;
6,578,086; 6,222,848; 6,130,877; 5,970,125; 6,807,174; 7,397,763; 7,664,123; 7,385,998; and 8,607,323 (collectively, the “Asserted
Patents”). The complaint alleges that Cisco has manufactured, sold, offered for sale and/or imported technology that infringes
the Asserted Patents. The Company is seeking relief in the form of a finding of infringement of the Asserted Patents, an accounting
of all damages sustained by the Company as a result of Cisco’s infringement, actual damages, enhanced damages under 35 U.S.C.
Section 284, attorney’s fees and costs. On July 8, 2014, the Company filed its amended complaint to reflect that certain
of the patents asserted were assigned to its wholly-owned subsidiary NNPT LLC (“NNPT”), based in Longview, Texas. By
the amended complaint, NNPT was added as a co-plaintiff with the Company. On August 5, 2014, Cisco filed a motion to dismiss certain
claims alleged in the amended complaint. On August 26, 2014, the Company and NNPT filed an opposition to Cisco’s motion to
dismiss. On September 5, 2014, Cisco filed its reply brief regarding its motion to dismiss. On March 9, 2015, Cisco moved to consolidate
certain claims relating to alleged obligations by the Company to license Cisco on two unrelated patents, which Cisco had made against
the Company on June 6, 2014 in the pending case
Bockstar Technologies LLC v. Cisco Systems, Inc.
, Case No. 1:13-cv-02020-
SLR-SRF (see below). On March 23, 2015, the Company filed its opposition to Cisco’s motion to consolidate. On March 31, 2015,
the Court granted Cisco’s motion to dismiss allegations of “willful” infringement. Spherix’s allegations
of patent infringement for the eleven (11) patents continue. Spherix has the ability to re-allege “willful” infringement
at a later time. On April 3, 2015, Cisco Systems, Inc. petitioned the U.S. Patent Office for an
inter partes
review (“IPR”)
of Spherix patents 7,397,763 and 8,607,323. The remaining nine patents Spherix has asserted against Cisco were not part of the
petitions and the time for Cisco to petition the USPTO for an IPR on those remaining patents expired on April 6, 2015. On April
10, 2015, Cisco withdrew its March 9, 2015 motion to consolidate claims from the
Bockstar
case. On May 5, 2015, Cisco filed
its Answer to the Company’s amended complaint with counterclaims under the Sherman Act, breach of contract, breach of covenant
of good faith and fair dealing implied in contract, promissory estoppel, and requesting a declaration that the patents at issue
are non-infringed and invalid. On June 10, 2015, the Court entered a Scheduling Order for the case. The Court set the
Markman
hearing to occur in two phases, for two different sets of patents, to occur on June 24, 2016 and September 8, 2016. The Court set
trial to begin on January 16, 2018. On July 13, 2015, the Company filed its oppositions to Cisco’s IPR petitions. On July
20, 2015, the Company filed a motion to dismiss or transfer certain of Cisco’s counterclaims. On September 22, 2015, the
PTAB issued orders instituting the two IPR proceedings, Nos. IPR2015-00999 and IPR2015-01001, as requested by Cisco. On November
23, 2015, the Company and RPX entered into the RPX License Agreement (see Note 7), which resolved all issues in this case. On December
3, 2015, the parties filed a Joint Motion to Dismiss, which the Court granted on December 4, 2015. On December 3, 2015, the parties
also filed a Joint Motion to Terminate in each of the two IPR proceedings, which the PTAB granted on December 4, 2015.
Spherix Incorporated v. Juniper Networks,
Inc., Case No. 1:14-cv-00578-SLR, in the United States District Court for the District of Delaware
On May 2, 2014, the Company initiated litigation
against Juniper Networks, Inc. (“Juniper”) in
Spherix Incorporated v. Juniper Networks, Inc.
, Case No. 1:14-cv-
00578-SLR, in the United States District Court for the District of Delaware for infringement of U.S. Patent Nos. RE40467; 6,578,086;
6,130,877; 7,385,998; 7,664,123; and 8,607,323 (collectively, the “Asserted Patents”). The complaint alleges that Juniper
has manufactured, sold, offered for sale and/or imported technology that infringes the Asserted Patents. The Company is seeking
relief in the form of a finding of infringement of the Asserted Patents, an accounting of all damages sustained by the Company
as a result of Juniper’s infringement, actual damages, enhanced damages under 35 U.S.C. Section 284, attorney’s fees
and costs. On July 8, 2014, the Company filed its amended complaint to reflect that certain of the patents asserted were assigned
to the Company’s wholly-owned subsidiary NNPT LLC, based in Longview, Texas. By the amended complaint, NNPT LLC was added
as a co-plaintiff with the Company. On August 8, 2014, Juniper filed a motion to dismiss certain claims alleged in the amended
complaint. On August 29, 2014, the Company filed its opposition to Juniper’s motion to dismiss. On September 15, 2014, Juniper
filed its reply brief regarding its motion to dismiss. On March 31, 2015, the Court granted Juniper’s motion to dismiss allegations
of “willful” infringement. Spherix’s allegations of patent infringement for the eleven (11) patents continue.
Spherix has the ability to reallege “willful” infringement at a later time. On April 14, 2015, Juniper filed its Answer
to the Company’s amended complaint. On May 6, 2015, the Court held an in-person Scheduling Conference in court and ordered
the parties to submit the final proposed Scheduling Order to the Court. On May 28, 2015, the Court entered a Scheduling Order for
the case setting the
Markman
hearing for June 24, 2016 and trial to begin on May 15, 2017. On November 23, 2015, the Company
and RPX entered into the RPX License Agreement (see Note 7), which resolved all issues in this case. On December 2, 2015, the parties
filed a Joint Motion to Dismiss, which the Court granted on December 4, 2015.
NNPT, LLC v. Huawei Investment &
Holding Co., Ltd. et al., Case No. 2:14-cv-00677-JRG-RSP, in the United States District Court for the Eastern District of Texas
On June 9, 2014, NNPT initiated litigation
against Futurewei Technologies, Inc., Huawei Device (Hong Kong) Co., Ltd., Huawei Device USA Inc., Huawei Investment & Holding
Co., Ltd., Huawei Technologies Co., Ltd., Huawei Technologies Cooperatif U.A., and Huawei Technologies USA Inc. (collectively “Huawei”),
in
NNPT, LLC v. Huawei Investment & Holding Co., Ltd. et al.
, Case No. 2:14-cv-00677-JRG-RSP, in the United States District
Court for the Eastern District of Texas (“the Court”), for infringement of U.S. Patent Nos. 6,578,086; 6,130,877; 6,697,325;
7,664,123; and 8,607,323 (collectively, the “Asserted Patents”). On September 8, 2014, Huawei filed its answers to
the complaint in which defendant Huawei Technologies USA asserted counterclaims requesting a declaration that the patents at issue
were non-infringed and invalid. On October 8, 2014, NNPT filed its Answer to the counterclaims, in which it denied that the Asserted
Patents were non-infringed and invalid. On January 20, 2015, the Court held a Scheduling Conference and set the
Markman
hearing for July 17, 2015 and trial to begin on February 8, 2016. On January 28, 2015, the Court appointed as mediator for the
parties, Hon. David Folsom, former Chief Judge of the United States District Court for the Eastern District of Texas. On February
24, 2015, the Court issued its Docket Control Order setting the
Markman
hearing for July 17, 2015 and trial to begin on
February 8, 2016. The Court also set an August 14, 2015 deadline to complete mediation. On June 11, 2015, Huawei filed a request
for
inter partes
review (“IPR”) of two of the Asserted Patents in the United States Patent and Trademark Office.
On July 7, 2015, the Court reset the
Markman
hearing date for August 5, 2015. The
Markman
hearing was held on August
5, 2015 as scheduled. The parties held an initial mediation on August 6, 2015. On August 17, 2015, the Court issued its
Markman
Order. On August 20, 2015, the mediator filed a report with the Court reporting that the parties reached a settlement of the case
on August 14, 2015. On August 31, 2015, the parties filed a Joint Motion to Stay and Notice of Settlement. On September 9, 2015,
the Court stayed the case and set a status conference for October 2, 2015. On September 18, 2015, the parties filed in the PTAB
a joint motion to terminate the two IPR petitions file by Huawei, Nos. IPR2015-01382 and IPR2015-01390. On September 24, 2015,
the PTAB issued orders terminating the two IPR proceedings. On October 13, 2015, the Company received Huawei’s fully executed
copy of a confidential settlement and license agreement (the “Agreement”). The Agreement provides Huawei with a fully
paid-up, non-exclusive, irrevocable, worldwide license (without the right to sub-license) to make, sell and otherwise dispose of
certain specifically listed licensed products under eleven (11) of the Company’s patents (the “License”). Hence,
the License is not a license to the Company’s entire portfolio. The Company agreed that it will not bring suit or otherwise
assert a claim with respect to the licensed products. In exchange for a one-time cash payment to the Company in the amount of $295,000,
the Company will have granted the License and an irrevocable release in law and equity of all claims and liabilities involved in
the Litigation. On November 16, 2015, the parties file a Stipulation of Dismissal and the Court ordered the case dismissed on November
17, 2015.
Spherix Incorporated v. Verizon Services
Corp. et al., Case No. 1:14-cv-00721-GBL-TCB, in the United States District Court for the Eastern District of Virginia
On June 11, 2014, the Company initiated
litigation against Verizon Services Corp.; Verizon South Inc.; Verizon Virginia LLC; Verizon Communications Inc.; Verizon Federal
Inc.; Verizon Business Network Services Inc.; and MCI Communications Services, Inc. (collectively, “Verizon”) in
Spherix Incorporated v. Verizon Services Corp. et al.
, Case No. 1:14-cv-00721-GBL-TCB, in the United States District Court
for the Eastern District of Virginia (“the Court”) for infringement of U.S. Patent Nos. 6,507,648; 6,882,800; 6,980,564;
and 8,166,533. On July 2, 2014, the Company filed its Amended Complaint in the case in which the Company added allegations of infringement
of U.S. Patent No. 7,478,167. On August 15, 2014, Verizon filed a motion to dismiss, or in the alternative, a motion for a more
definite statement. On September 9, 2014, the Court issued a Scheduling Order adopting the parties’ Joint Proposed Discovery
Plan. According to the Scheduling Order, the
Markman
hearing is currently scheduled for March 16, 2015. On September 12,
2014, the Company filed its opposition to Verizon’s motion to dismiss, and on September 26, 2014, Verizon filed its reply
brief. On October 3, 2014, the Court held a hearing on the motion to dismiss and issued a Minute Entry stating that motion was
denied. The Court stated that an Order would follow. On October 17, 2014, Verizon filed its Answer to the Company’s Amended
Complaint. The parties agreed to narrow the case by dismissing without prejudice the claims under U.S. Patent Nos. 6,507,648 and
6,882,800, with each party to bear its own costs and attorneys’ fees as to the dismissed claims. The parties filed a joint
motion to that effect on October 27, 2014, which was granted on October 30, 2014. The parties further agreed to narrow the case
by dismissing without prejudice the claims under U.S. Patent Nos. 8,166,533 and 7,478,167, and filed a joint motion to that effect
on November 6, 2014. On November 13, 2014, the Court granted the parties’ Joint Motion to Dismiss the ‘533 Patent and
the ‘167 Patent without prejudice, with each party to bear its own costs and attorneys’ fees as to the dismissed claims.
On December 18, 2014, the Court set the case for a five-day trial beginning on May 18, 2015. On January 9, 2015, the Company and
Verizon each filed their motions for summary adjudication and entry of proposed claim constructions. On January 12, 2015, the Court
set the motions for summary adjudication for hearing on March 16, 2015 along with the
Markman
hearing. On January 22, 2015,
the parties filed their oppositions to the motions for summary adjudication and entry of proposed claim constructions, and on February
5, 2015, the parties filed their reply briefs. On March 16, 2015, the Court held the
Markman
hearing as scheduled. On March
25, 2015, the Court reset the May 18, 2015 jury trial date to August 10, 2015. On March 25, 2015, the Court clarified that the
trial will be held on August 10, 11, 12, 13 and 17 of 2015. On, June 11, 2015, Verizon filed a request for
inter partes
review (“IPR”) of the Asserted Patent in the United States Patent and Trademark Office. On July 1, 2015, the Court
granted Verizon’s motion for summary judgment as to indefiniteness and non-infringement. On July 30, 2015, the Company filed
a Notice of Appeal of the Court’s judgment in the United States Court of Appeals for the Federal Circuit. On August 31, 2015,
a settlement agreement between Spherix and Verizon was entered into, resolving all outstanding litigation between the two companies.
On September 4, 2015, the Company filed an unopposed motion to withdraw its Notice of Appeal. On September 8, 2015, the Court granted
the motion to withdraw the Notice of Appeal. On September 10, 2015, the parties filed a joint motion to terminate the IPR proceeding.
On September 14, 2015, the PTAB terminated Verizon’s petition.
Spherix Incorporated v. Verizon Services
Corp. et al., Case No. 1:15-cv-0576-GBL-IDD, in the United States District Court for the Eastern District of Virginia
On May 1, 2015, the Company initiated litigation
against Verizon Services Corp.; Verizon South Inc.; Verizon Virginia LLC; Verizon Communications Inc.; Verizon Federal Inc.; Verizon
Business Network Services Inc.; MCI Communications Services, Inc.; Cellco Partnership d/b/a Verizon Wireless; and Cisco Systems,
Inc. (collectively, “Defendants”) in
Spherix Incorporated v. Verizon Services Corp. et al
, Case No. 1:15-cv-0576-GBL-IDD,
in the United States District Court for the Eastern District of Virginia for infringement of U.S. Patent Nos. 5,959,990; 6,111,876;
RE40,999; RE44,775; RE45,065; RE45,081; RE45,095; and RE45,121 (collectively, the “Asserted Patents”). The complaint
alleges that Defendants has used, manufactured, sold, offered for sale and/or imported technology that infringes the Asserted Patents.
The Company is seeking relief in the form of a finding of infringement of the Asserted Patents, damages sufficient to compensate
the Company for Defendants’ infringement, together with pre-and post-judgment interest and costs, and the Company’s
attorney’s fees. On June 30, 2015, the Company filed its Amended Complaint to add allegations of infringement of U.S. Patent
Nos. RE45,521 and RE45,598. On July 15, 2015, Cisco filed a motion to transfer the case to the District of Delaware. On July 17,
2015, Verizon filed its Answer and Counterclaims to the Complaint. On July 17, 2015, the Court issued a Scheduling Order setting
the Final Pretrial Conference for November 19, 2015, with trial to be set within 4-8 weeks of the pretrial conference. On July
31, 2015, the Company filed its Opposition to Cisco’s motion to transfer. On August 5, 2015, the Court held an Initial Pretrial
Conference in the case to discuss the discovery plan for the case. On August 6, 2015, the Company filed its answer to Verizon's
counterclaims. On August 11, 2015, the Court issued its Scheduling Order regarding the discovery schedule, setting discovery to
be concluded by November 15, 2015. On August 31, 2015, a settlement agreement between Spherix and Verizon was entered into, resolving
all outstanding litigation between the two companies. Cisco was not a party to the agreement and the case continues against Cisco.
On September 1, 2015, the Company and Verizon filed a joint motion to dismiss the Verizon entities from the case. On September
2, 2015, the Court granted the motion to dismiss Verizon. On September 23, 2015, Cisco filed a Consent Motion to transfer the action
to the District of Delaware, and on September 25, 2015, the Court granted the motion. The case has been transferred to the District
of Delaware and assigned new case number 1:15-cv-00869-SLR “(Delaware Case”). On November 23, 2015, the Company and
RPX entered into the RPX License Agreement (see Note 7), which resolved all issues in the Delaware Case. On December 3, 2015, the
parties filed a Joint Motion to Dismiss, which the Court granted on December 4, 2015.
Cisco Systems, Inc. v. Spherix Incorporated,
1:15-cv-00559-SLR, in the United States District Court for the District of Delaware
On June 30, 2015, Cisco Systems, Inc. initiated
litigation against the Company in United States District Court for the District of Delaware, requesting a declaration of non-infringement
U.S. Patent No. RE45,598, which issued on June 30, 2015, and, with respect to that patent, alleging breach of contract, breach
of covenant of good faith and fair dealing implied in contract and promissory estoppel. On August 28, 2015, the Company filed motions
to dismiss the case in light of previously filed case, case No. 1:15-cv-0576-GBL-IDD, in the Eastern District of Virginia, which
involves U.S. Patent No. RE45,598. On November 23, 2015, the Company and RPX entered into the RPX License Agreement (see Note 7),
which resolved all issues in this case. On December 3, 2015, the parties filed a Joint Motion to Dismiss, which the Court granted
on December 4, 2015.
Spherix Incorporated v. Fairpoint Communications,
Inc., Case No. 1:16-cv-00305-RGA, in the United States District Court for the District of Delaware
On April 26, 2016, the Company initiated
litigation against Fairpoint Communications, Inc. in
Spherix Incorporated v. Fairpoint Communications, Inc.
, Case No. 1:16-cv-00305-RGA,
in the United States District Court for the District of Delaware for infringement of U.S. Patent No. RE40,999 (the ‘999 Patent”).
The Company is seeking relief in the form of a finding of infringement of the ‘999 Patent, damages sufficient to compensate
the Company for Defendants’ infringement together with pre-and post-judgment interest and costs, a declaration that the case
is exceptional under 35 U.S.C. § 285, and the Company’s attorney’s fees.
Spherix Incorporated v. Level 3 Communications,
Inc. et al., Case No. 1:16-cv-00307-RGA, in the United States District Court for the Eastern District of Virginia
On April 26, 2016, the Company initiated
litigation against Level 3 Communications, Inc. and TW Telecom, Inc. in
Spherix Incorporated v. Level 3 Communications, Inc.
et al.
, Case No. 1:16-cv-00307-RGA, in the United States District Court for the District of Delaware for infringement of U.S.
Patent No. RE40,999 (the ‘999 Patent”). The Company is seeking relief in the form of a finding of infringement of the
‘999 Patent, damages sufficient to compensate the Company for Defendants’ infringement together with pre-and post-judgment
interest and costs, a declaration that the case is exceptional under 35 U.S.C. § 285, and the Company’s attorney’s
fees.
Counterclaims
In the ordinary course of business, the
Company, along with the Company’s wholly-owned subsidiaries, will initiate litigation against parties whom the Company believe
have infringed on intellectual property rights and technologies. The initiation of such litigation exposes us to potential counterclaims
initiated by the defendants. Currently, as stated above, defendants in the case
Spherix Incorporated v. Uniden Corporation
have filed counterclaims against the Company. The Company has evaluated the counterclaims and believe they are without merit and
have not recorded a loss provision relating to such matters. The Company can provide no assurance that the outcome of these claims
will not have a material adverse effect on the Company’s financial position and results from operation.
Note 9. Compensatory Arrangements
On May 20, 2016, the Company entered into
a new employment agreement with the Company’s CEO, Anthony Hayes (the “Employment Agreement”) retroactively effective
to April 1, 2016. Pursuant to the terms of the Agreement, Mr. Hayes will be paid an annual base salary of $350,000 (“Base
Salary”) and a target annual bonus opportunity equal to a maximum of 100% of the Base Salary upon the achievement of certain
milestones as agreed to by the Compensation Committee of the Board of Directors. There has been no increase in the dollar amounts
of the base salary or maximum target bonus amounts from the prior effective employment agreement of Mr. Hayes. In the event that
Mr. Hayes’ employment is terminated by the Company without “cause” or by Mr. Hayes for “good reason”
(each as defined in the Employment Agreement), Mr. Hayes will be entitled to receive, subject to his execution and non-revocation
of a separation and release agreement, a separation payment in the amount of one year’s base salary at the then-current rate
payable, plus any payment on a pro-rated basis for any bonus earned in connection with any bonus plan to which he was a participant
at the date of such termination within thirty days of such termination.
The employment agreement with Mr. Hayes
also contains customary confidentiality, noncompetition, non-solicitation and non-disparagement provisions.
In addition, as previously disclosed, Mr. Hayes was granted an award of restricted stock units totaling
118,512 shares of common stock, which will vest upon the achievement of certain agreed upon milestones.
Note 10. Assignment and Assumption of
Rights Agreement with TOI
On June 16, 2012, the Company and Transfer Online, Inc. (“TOI”) entered into an Assignment
and Assumption
of Rights Agreement (the “Assignment”)
to that certain Rights Agreement, effective January 1, 2013 (valid through December 31, 2017, referred to herein as the “Rights
Agreement”) originally entered into between the Company and Equity Stock Transfer (“EST”), and previously filed
by the Company on Form 8-K with the Securities and Exchange Commission on January 30, 2013. The Assignment of the Rights Agreement
replaced EST as the Rights Agent and to appoint TOI as the successor Rights Agent on July 15, 2016.
|
Note 11.
|
Subsequent Event
|
On August 2, 2016, pursuant to the Company’s
effective shelf registration statement on Form S-3 (No. 333-198498), and the prospectus supplements filed thereto, the Company
entered into an underwriting agreement (the “Underwriting Agreement”) with Laidlaw & Company (UK) Ltd. as
representative of the several underwriters listed on Schedule I thereto (the “Underwriters”), relating to the public
offering and sale of up to 1,592,357 shares of the Company’s common stock at a price to the public of $1.57 per share.
Under the terms of the Underwriting Agreement, the Company has granted the representative of the underwriters a 30-day option to
purchase up to 231,349 additional shares of its common stock. The gross proceeds to the Company were $2,500,000, before deducting
the underwriting discount and other estimated offering expenses payable by the Company assuming no exercise by the Underwriters
of their over-allotment option, or $2,863,218 if the Underwriters exercise their over-allotment option. The sale of such 1,592,357
shares closed on August 8, 2016.